



Correction to: Evidence-based approach to active surveillance of prostate cancer

Luke Witherspoon¹ · Rodney H. Breau^{1,2} · Luke T. Lavallée^{1,2} 

Published online: 12 December 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Correction to: World Journal of Urology
<https://doi.org/10.1007/s00345-019-02662-5>

In the original publication of the article, the values in the columns “**Gleason Score**” and “**Clinical Stage**” under the section **Urologic Organization Guidelines** were incorrect in Table 1. Now, the values have been exchanged from their incorrect position to their correct position, and the correct Table 1 is given below:

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s00345-019-02662-5>.

✉ Luke T. Lavallée
lulavallee@toh.ca

¹ Division of Urology, Department of Surgery, The Ottawa Hospital and University of Ottawa, General Campus, Ottawa, Canada

² Ottawa Hospital Research Institute, 501 ch. Smyth Rd, Box/C.P. 222, Ottawa, ON K1H 8L6, Canada

Table 1 Summary of active surveillance enrollment criteria

Institution/urologic organization	Gleason score	PSA (ng/mL)	Clinical stage	Minimum number of cores taken at biopsy	Maximum number of positive cores	Maximum percentage of any biopsy core positive
Individual cohort criteria						
University of Toronto [5]	≤ 3+3	≤ 10	T2	8	–	–
John Hopkins [6]	≤ 3+3	–	≤ T1c	12	2	50%
Prostate Cancer Research International Active Surveillance (PRIAS) Criteria [7]	≤ 3+3	≤ 10	≤ T2c	10	2	–
Memorial Sloan Kettering Cancer Center (MSKCC) [8]	≤ 3+3	< 10	≤ T2a	10	3	50%
St. Vincent's, Australia [9]	≤ 3+3	< 10	≤ T2b	10	< 20% of total cores	< 30%
Canary Prostate Cancer Active Surveillance Study (PASS) [11]	≤ 3+4	< 20	≤ T2c	≥ 10	< 34% of total cores	–
Urologic organization guidelines						
American Urology Association (AUA) [3]	≤ 3+3	≤ 10	≤ T2a	–	–	–
Cancer Care Ontario (CCO) [2]	≤ 3+3	–	≤ T2a	–	–	–
	≤ 3+4	–	–	–	–	< 10% total tumor
European Association of Urology (EAU) [4]	≤ 3+3	≤ 10	≤ T2a	–	–	–
National institute for Health and Care Excellence (NICE) [15]	≤ 3+3	≤ 10	≤ T2a	–	–	–